GRAIL is trading at $121.74, down 10.13%, as coverage attributed pressure to profit-taking after a roughly 85% one-month rally. - No new GRAIL corporate announcement was identified for October 16. Coverage also noted elevated valuation and a director’s Form 144 filing to sell 5,000 shares, without establishing that the filing caused the decline. - The Nasdaq fell 1.36% and biotech ETF XBI fell 2.06%, consistent with broader risk-off pressure, though this alone does not explain the full move.